MedTrace Logo

Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid

NCT03188146 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2025-03-24

No results posted yet for this study

Summary

Several risk assessment scoring systems have been proposed to assess the therapeutic response and predict long term prognosis in ursodeoxycholic acid (UDCA)-treated primary biliary cholangitis (PBC) patients, in order to risk stratify PBC patients and guide their management. However there scoring systems have not been fully validated in Chinese population. This study is going to compare the prognostic ability of these criteria, validate the overseas scoring systems, develop and validate a new scoring system in a cohort of Chinese PBC patients.

Conditions

  • Primary Biliary Cholangitis (PBC)

Interventions

DRUG

Ursodeoxycholic Acid

Standard care of PBC patients

Sponsors & Collaborators

  • Beijing 302 Hospital

    collaborator OTHER

  • Humanity and Health Research Centre

    lead OTHER

Principal Investigators

  • George Lau, MD, PhD · Humanity and Health Medical Centre

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2025-02-15
Completion
2025-02-15
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03188146 on ClinicalTrials.gov